Payment overview · 2025
General Payments
$2,793.08
161 reported records · 25 companies
Healthcare provider profile · identity verified
William Clever, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · JOHNSON CITY, TN · NPI 1982608758
Verified facts
What the public records show
CMS Open Payments records show William Clever, FNP received $2,793.08 in general payments during 2025 across 161 reported records.
ABBVIE INC. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Caplyta, Eliquis, Ingrezza, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Qulipta, Rexulti, Rybelsus, Trelegy Ellipta, Ubrelvy, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Myrbetriq by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 300 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 586 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 300 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 349 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Rexulti by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $525.69 | 18.8% | 37 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $301.53 | 10.8% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $271.08 | 9.7% | 18 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $232.43 | 8.3% | 15 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $169.06 | 6.0% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $157.44 | 5.6% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $131.93 | 4.7% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $131.86 | 4.7% | 9 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $89.44 | 3.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $89.28 | 3.2% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $84.34 | 3.0% | 3 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $82.47 | 3.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.21 | 2.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $66.37 | 2.4% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $64.01 | 2.3% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $61.54 | 2.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.10 | 1.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.07 | 1.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $35.51 | 1.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $33.22 | 1.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.60 | 1.1% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $30.88 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.83 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.90 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.29 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,793.08 | 161 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $408.17 | 23 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $295.65 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $205.02 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $183.40 | 10 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $157.44 | 11 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $157.44 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $156.72 | 18 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $131.93 | 6 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $125.79 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $114.43 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $109.14 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $89.28 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $87.73 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $84.34 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $83.23 | 5 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $82.47 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $73.32 | 7 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $67.21 | 3 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $66.92 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $66.37 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.37 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $64.01 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $62.50 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $61.54 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $59.92 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $38.95 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $38.95 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $33.22 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.60 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $30.88 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 245 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 300 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 102 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 349 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 81 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 586 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
102 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
300 | 78 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
245 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
586 | 125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
300 | 78 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
349 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 795 | 141 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 792 | 131 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 600 | 155 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 586 | 125 |
| Lisinopril | Lisinopril | 567 | 168 |
| Potassium Chloride | Potassium Chloride | 511 | 137 |
| Omeprazole | Omeprazole | 486 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 434 | 110 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 422 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 120 |
| Furosemide | Furosemide | 411 | 123 |
| Mounjaro | Tirzepatide | 349 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 346 | 91 |
| Alprazolam | Alprazolam | 336 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 335 | 98 |
| Jardiance | Empagliflozin | 300 | 78 |
| Trazodone Hcl | Trazodone Hcl | 279 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 247 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 245 | 61 |
| Eliquis | Apixaban | 245 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 63 |
| Famotidine | Famotidine | 231 | 63 |
| Losartan Potassium | Losartan Potassium | 227 | 66 |
| Ibuprofen | Ibuprofen | 226 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 226 | 67 |
| Meloxicam | Meloxicam | 223 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 213 | 73 |
| Tizanidine Hcl | Tizanidine Hcl | 201 | 47 |
| Ondansetron Hcl | Ondansetron Hcl | 198 | 79 |
| Sertraline Hcl | Sertraline Hcl | 193 | 48 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 174 | 59 |
| Diazepam | Diazepam | 170 | 39 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 164 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 53 |
| Clonazepam | Clonazepam | 163 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 51 |
| Allopurinol | Allopurinol | 155 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 146 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 143 | 26 |
| Alendronate Sodium | Alendronate Sodium | 142 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 40 |
| Celecoxib | Celecoxib | 136 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 136 | 32 |
| Ozempic | Semaglutide | 136 | 35 |
| Metformin Hcl | Metformin Hcl | 134 | 34 |
| Azithromycin | Azithromycin | 131 | 103 |
| Buspirone Hcl | Buspirone Hcl | 126 | 38 |
| Montelukast Sodium | Montelukast Sodium | 123 | 38 |
| Fluconazole | Fluconazole | 122 | 54 |
| Simvastatin | Simvastatin | 122 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 120 | 32 |
| Pregabalin | Pregabalin | 116 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 34 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 111 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 104 | 29 |
| Linzess | Linaclotide | 102 | 25 |
| Prednisone | Prednisone | 102 | 56 |
| Carvedilol | Carvedilol | 101 | 23 |
| Lorazepam | Lorazepam | 101 | 17 |
| Promethazine Hcl | Promethazine Hcl | 100 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 13 |
| Spironolactone | Spironolactone | 92 | 31 |
| Mirtazapine | Mirtazapine | 88 | 32 |
| Ondansetron Odt | Ondansetron | 88 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 19 |
| Nitroglycerin | Nitroglycerin | 85 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 23 |
| Rexulti | Brexpiprazole | 81 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 77 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 77 | 14 |
| Propranolol Hcl | Propranolol Hcl | 77 | 21 |
| Torsemide | Torsemide | 75 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 73 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 14 |
| Lovastatin | Lovastatin | 71 | 17 |
| Vraylar | Cariprazine Hcl | 71 | suppressed |
| Amoxicillin | Amoxicillin | 70 | 58 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 70 | 55 |
| Bupropion Hcl Sr | Bupropion Hcl | 68 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 68 | 18 |
| Entresto | Sacubitril/Valsartan | 68 | 17 |
| Methocarbamol | Methocarbamol | 68 | 20 |
| Estradiol | Estradiol | 67 | 14 |
| Tramadol Hcl | Tramadol Hcl | 64 | 16 |
| Xarelto | Rivaroxaban | 59 | 15 |
| Topiramate | Topiramate | 58 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 57 | 13 |
| Methylprednisolone | Methylprednisolone | 55 | 44 |
| Chlorthalidone | Chlorthalidone | 54 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 28 |
| Nystatin | Nystatin | 52 | 30 |
| Qulipta | Atogepant | 52 | suppressed |
| Gemfibrozil | Gemfibrozil | 49 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 48 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 18 |
| Midodrine Hcl | Midodrine Hcl | 48 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 42 |
| Atenolol | Atenolol | 47 | 15 |
| Doxepin Hcl | Doxepin Hcl | 47 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 45 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 45 | 32 |
| Bupropion Xl | Bupropion Hcl | 44 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 27 |
| Levetiracetam | Levetiracetam | 44 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 17 |
| Lamotrigine | Lamotrigine | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 30 |
| Kerendia | Finerenone | 39 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 11 |
| Temazepam | Temazepam | 38 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 37 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 36 | 13 |
| Lidocaine | Lidocaine | 36 | 15 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 23 |
| Olanzapine | Olanzapine | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | 12 |
| Ketoconazole | Ketoconazole | 30 | 12 |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Erythromycin | Erythromycin Base | 28 | 17 |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 20 |
| Nurtec Odt | Rimegepant Sulfate | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Ubrelvy | Ubrogepant | 25 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 17 |
| Primidone | Primidone | 24 | suppressed |
| Abilify Maintena | Aripiprazole | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 17 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Humira(Cf) Pen | Adalimumab | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Epinephrine | Epinephrine | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Caplyta | Lumateperone Tosylate | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | 11 |
| Lamotrigine Er | Lamotrigine | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 13 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,793.08 · 161 records | ABBVIE INC. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, Auvelity, Briviact, CAPLYTA, COBENFY, CREON, Da Vinci Surgical System, Dexcom G6 Transmitter, ELIQUIS, FANAPT, GVOKE HYPOPEN, HETLIOZ, IBSRELA, INGREZZA, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, Nayzilam, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Maintena play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error